蒂卡格勒罗和普拉苏格勒对冠状动脉微循环的影响在选择性皮肤穿透冠状动脉干预中
Fabio Mangiacapra1,2, Iginio Colaiori3, Giuseppe Di Gioia3
1Research Unit of Cardiovascular Science, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
Heart (British Cardiac Society)
|June 14, 2023
概括
与prasugrel相比,Ticagrelor在皮肤冠状动脉干预 (PCI) 后改善了冠状动脉血流和微血管功能. 这表明,在接受PCI的稳定冠状动脉疾病 (CAD) 患者中,提卡格雷勒可能会减少心肌损伤.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 冠状动脉疾病 (CAD) 的管理往往涉及皮肤冠状动脉干预 (PCI).
- 像蒂卡格勒罗和普拉苏格勒这样的P2Y12抑制剂对于预防PCI后的血栓事件至关重要.
- 除了血小板抑制之外,蒂卡格勒罗对冠状动脉微循环的潜在影响需要进行调查.
研究的目的:
- 为了比较蒂卡格勒勒与普拉苏格勒对冠状动脉血流 (Q) 和微血管抵抗 (R) 的影响,在接受选择性PCI的稳定CAD患者中.
- 评估这些药物对PCI后心肌损伤标志物的影响.
主要方法:
- 一项随机试验,涉及50名接受PCI的稳定CAD患者.
- 患者在PCI前至少12小时接受了提卡格雷勒 (180毫克) 或普拉苏格雷尔 (60毫克) 的充填剂量.
- 冠状动脉血流 (Q) 和微血管阻力 (R) 用PCI前后连续热稀释来测量.
- 监测了血小板的反应性和I型热波宁水平.
主要成果:
- 与普拉苏格雷尔组相比,提卡格雷勒组在PCI后的冠状动脉血流量 (Q) 显著增加,微血管阻力 (R) 降低.
- 较高的血小板反应性与降低的Q和增加的R相关.
- 术周心肌损伤,以托波I水平为指标,在提卡格雷勒组显著较低.
结论:
- 与普拉苏格勒相比,提卡格勒的预治疗在稳定的CAD患者中增强了PCI后的冠状动脉流动和微血管功能.
- 提卡格似乎具有保护作用,减少了与PCI相关的肌心损伤.
- 这些发现凸显了蒂卡格勒罗在优化PCI后微血管结果方面的潜在益处.
相关概念视频
01:28Acute Coronary Syndrome IV: Interprofessional Care
13
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
13
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
01:30Acute Coronary Syndrome I: Introduction
33
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
33
01:27Peripheral Artery Disease III: Interprofessional Care
13
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
13
01:27Coronary Artery Disease V: Interprofessional Care
11
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
11
01:30Acute Coronary Syndrome III: Diagnostic Studies
11
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
11